{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:43:48Z","timestamp":1773337428100,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The treatment for relapsed\/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti\u2010apoptotic protein BCL\u20102, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax\u2010based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non\u2010haematologic toxicities, most commonly gastrointestinal upset, were observed.<\/jats:p>","DOI":"10.1111\/bjh.16454","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T20:10:41Z","timestamp":1580760641000},"page":"1136-1140","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Real\u2010world data on safety and efficacy of venetoclax\u2010based regimens in relapsed\/refractory t(11;14) multiple myeloma"],"prefix":"10.1111","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-9684","authenticated-orcid":false,"given":"Diana","family":"Basali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Cleveland Clinic Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rybicki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Rosko","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryann","family":"Karam","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Schlueter","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Dysert","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.8004"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25331"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.046"},{"key":"e_1_2_7_9_1","unstructured":"Loewe K.(2019)AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality. Available at:https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-announces-us-fda-lifts-partial-clinical-hold-on-phase-3-study-venetoclax-in-patients-with-multiple-myeloma-positive-for-t1114-genetic-abnormality.htm. (Accessed December 2 2019)."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2018.02.002"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788323"},{"key":"e_1_2_7_12_1","article-title":"The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia","author":"Nalghranyan S.","year":"2019","journal-title":"American Journal of Hematology"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0730"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0223-9"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16454","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T19:44:51Z","timestamp":1693424691000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/bjh.16454"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16454","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,3]]},"assertion":[{"value":"2019-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}